On the issue of adjuvant therapy of Helicobacter pylori infection: focus on probiotics and prebiotics. A review

The aspects of using various adjuvant therapy options for Helicobacter pylori infection considered in the article are of great practical importance and ensure the optimization of the management of patients infected with this microorganism. For patients with erosive and ulcerative lesions of the gastric mucosa, bismuth tripotassium dicitrate may be the drug of choice, for patients with chronic atrophic gastritis, alpha-glutamyl-tryptophan will help to provide local cytoprotection and regression of gastric mucosa atrophy, rebamipide may be effective for restoring epithelial permeability, and probiotics and prebiotics provide both increased effectiveness of pathogen eradication and a decrease in side effects and improvement of patients' health by correcting disorders of the microbiota of the gastrointestinal tract, the health and balance of which is the key to human health. It is also important to find the best probiotic / sinbiotic / autoprobiotic strain / combination of several indigenous strains for each patient for the best clinical result and eradication rate. It is the actual aim for next investigations.